Kittai Adam S, Blank Jessica, Graff Julie N
Oncology (Williston Park). 2018 Dec 17;32(12):599-602, 604-6.
Androgen deprivation therapy (ADT) comes in several forms, such as surgical castration or medical castration using gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist therapy. ADT is a critical treatment for high-risk and metastatic prostate cancer. There are important differences between GnRH agonists and antagonists. Here we review the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix. We also comment on the potential risks and benefits of degarelix, particularly when it comes to cardiovascular health. Finally, we describe an oral GnRH antagonist, which is not currently used in prostate cancer, but is included for completeness.
雄激素剥夺疗法（ADT）有多种形式，如手术去势或使用促性腺激素释放激素（GnRH）激动剂或GnRH拮抗剂疗法进行药物去势。ADT是高危和转移性前列腺癌的关键治疗方法。GnRH激动剂和拮抗剂之间存在重要差异。在此，我们回顾GnRH激动剂和拮抗剂的作用机制以及促成地加瑞克获批的研究。我们还对地加瑞克的潜在风险和益处进行评论，特别是在心血管健康方面。最后，我们描述一种口服GnRH拮抗剂，其目前未用于前列腺癌治疗，但为全面起见将其纳入。
